Authors: Sabina B. Aleixo, Narelle Parmanhane, Jose Zago Pulido
Published: 2022-06-06
DOI: 10.1200/jco.2022.40.16_suppl.e22515
Source: Full article
e22515 Background: Lung Cancer (LC) is one of the most common neoplasm of all malignant tumors, with an increasing lethality and incidence, corresponding to 13.5% of all types of cancer. The world estimate for 2020 was 19 million cases of cancer worldwide, with 10 million deaths of which lung cancer represented 18% of the deaths. It is estimated that in Brazil, according to INCA (National Cancer Center of Brazil) that in the year 2022 there will be 30,200 new cases, the second most common among men and the fourth among women. Unfortunately most cases are diagnosed in late stages and have low survival. Methods: Retrospective study of data from SisRHC (brazilian cancer registry system) of patients diagnosed with LC, treated at the reference cancer center Hospital Evangélico de Cachoeiro de Itapemirim/ES, from January 1, 2010 to December 31, 2019. Results: A total of 440 patients were included and their main characteristics at diagnoses was advanced stages (73.2% III/IV) and only 58 % where able to receive first line treatment: chemotherapy concomitantly with radiotherapy (22,3%), isolated chemotherapy (21.4%) and isolated radiotherapy (14.6%). After first line treatment outcome status was death (49.4%) and disease progression (12.3%). Median survival was 10.3 months. Conclusions: Despite the limitations of the retrospective study these data are important for understanding the pattern of disease in a developing country where acess to health is limited. Unfortunately the barrier of 12 months survival common in developed nations is still not a brazilian reality. Public policies are necessary for improvement